A Phase I, Open-Label, Randomized, Single-Center, Parallel Design Study Evaluating Pharmacokinetics of CaPre (Omega-3 Phospholipid) Following Single and Multiple Oral Doses in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2017
At a glance
- Drugs Omega-3 phospholipid (Primary)
- Indications Hypertriglyceridaemia
- Focus Pharmacokinetics
- 22 Aug 2017 New trial record
- 14 Aug 2017 According to an Acasti Pharma media release, select data from this and other studies (TRIFECTA, COLT and PMRI2016-4010) will be submitted for publication in a peer-reviewed journal.
- 14 Aug 2017 Results from this study were included in an oral presentation at the International Academy of Cardiology Annual Scientific Sessions 22nd World Congress on Heart Disease (WCHD), according to an Acasti Pharma media release.